Maintenance treatment with infliximab for the management of Crohn's disease in adults

Renato Caviglia, Ivo Boskoski, Michele Cicala, Carlo Maria Cicala

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Crohn's disease (CD) is a chronic, relapsing disease, the continuous cycle of which deeply affects the long-term course which, eventually, leads to fi brosis and development of transmural complications. It is well known that CD is an immune-mediated clinical condition and that tumor necrosis factor-α (TNF-α) plays a fundamental role in the pathogenesis of the disease. Current clinical guidelines recommend that patients with mild to moderate active CD should be treated initially with corticosteroids. Although this approach is effective in inducing remission, some patients may become dependent on, or refractory to, these drugs in the long term, thus increasing the risk of developing steroid-related adverse effects. A recent Cochrane systematic review established that infl iximab (IFX) is effective in inducing remission in patients with CD. Although only a few published studies have assessed IFX for the maintenance of remission in the long term, there is evidence that IFX is superior to placebo in sustaining clinical remission and fi stula healing; moreover, corticosteroid-sparing effects have been demonstrated. IFX is associated with the formation of antibodies to IFX which can lead to infusion reactions and shorter duration of response, but when comparing episodic vs scheduled maintenance treatment, the latter appears to sensibly reduce immunogenicity, thus offering improved effi cacy and tolerance. The fi nal point to consider is the best time to introduce IFX in the therapeutic algorithm of CD. Early use of IFX has been suggested to be more effective than late, and may potentially change the natural history of the disease. Effective induction and maintenance therapy with IFX is the only means with which to maintain long-lasting clinical and mucosal remission which, in turn, may modify the long-term course of the disease. Furthermore, when treating inflammatory bowel disease patients with IFX, an appropriate risk-benefit balance has to be taken into consideration, because the precise risk of serious adverse events associated with anti-TNF treatment in CD remains to be fully elucidated. © 2009 Caviglia et al, publisher and licensee Dove Medical Press Ltd.
Lingua originaleEnglish
pagine (da-a)39-49
Numero di pagine11
RivistaBIOLOGICS
Volume3
DOI
Stato di pubblicazionePubblicato - 2009

Keywords

  • Crohn's disease
  • Inflammatory bowel disease
  • Infliximab therapy
  • Steroid sparing
  • Tumor necrosis factor-α

Fingerprint

Entra nei temi di ricerca di 'Maintenance treatment with infliximab for the management of Crohn's disease in adults'. Insieme formano una fingerprint unica.

Cita questo